Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection

Preparative Biochemistry and Biotechnology

Volumn 33, Issue 1, 2003, Pages 29-38

  Marin, Milenen Hernández ^a   Bocalandro, Yadaris Márquez ^a   Vallejo, René Vázquez ^a   Tanty, Chryslaine Rodríguez ^b   Clark, David Higginson ^b   Peña, Lilliam Pozo ^a   León, Carlos Silva ^a  

^a Immunoassay Center Cuba   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Chimeric synthetic peptide; Gp46; HTLV II; P19; UMELISA

Indexed keywords

GENE PRODUCTS, ENV; HTLV-II ANTIGENS; HUMANS; LEUKEMIA, T-CELL, HTLV-II-ASSOCIATED; MICROTUBULE PROTEINS; PEPTIDES; PHOSPHOPROTEINS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE PROTEINS, ONCOGENIC; STATHMIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2;

EID: 0037246460     PISSN: 10826068     EISSN: None     Source Type: Journal    
DOI: 10.1081/PB-120018367     Document Type: Article

References (20)

1. Kalyanaraman, V.S.; Sarngadharan, M.G.; Robert-Guroff, M.; Miyoshi, I.; Golde, D.; Gallo, R.C. A new subtype of human T-cell leukemia virus (HTLV-II) associate with T a cell variant of hairy cell leukemia. Science 1982, 218, 571-573.
2. Rosenblatt, D.; Golden, D.W.; Wahchsman, W. A second isolate of HTLV-II associate with atypical hairy-cell leukemia. New Engl. J. Med. 1986, 315, 372-377.
3. Maloney, E.M.; Armien, B.; Gracia, F.; Castillo, L.; Kruger, H.; Levin, A.; Levine, P.H.; Kaplan, J.E.; Blattner, W.A.; Glusti, R.M. Risk factors for human T cell lymphotropic virus type II infection among the Guaymi Indians of Panama. J. Infect. Dis. 1999, 180 (3), 876-879.
4. Medeot, S.; Nates, S.; Recalde, A.; Gallego, S.; Maturano, E.; Giordano, M.; Serra, H.; Reategui, J.; Cabezas, C. Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Am. J. Trop. Med. Hyg. 1999, 60 (4), 623-629.
5. Arango, C.; Maloney, E.; Rugeles, M.T.; Bernal, E.; Bernal, C.; Borrero, I.; Herrera, S.; Restrepo, M.; Espinal, A.; Blattner, W.A. HTLV-I and HTLV-II coexist among the Embera and Inga Amerindians of Colombia. J. Acq. Immune. Defic. Syndr. Hum. Retrovirol. 1999, 20 (1), 102-103.
6. Safaeian, M.; Wilson, L.E.; Taylor, E.; Thomas, D.L.; Vlahov, D. HTLV-II and bacterial infections among injection drug users. J. Acq. Immune. Defic. Syndr. 2000, 24 (5), 483-487.
7. Lee, H.H.; Shih, J.; O'Donnell, D.; Swanson, P.; Mann, T.; Allain, J.P. Differential serological diagnosis of HTLV-I and HTLV-II infection by external membrane protein peptide-based enzyme immunoassays. Clin. Diag. Virol. 1997, 8 (1), 9-16.
8. Tanaka, Y.; Tanaka, R.; Hoshino, H. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II). Intl. J. Cancer. 1994, 59 (5), 655-660.
9. Hernández, M.; Selles, M.E.; Pozo, L.; Gómez, I.; Melchor, A. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation. Biochem. Biophys. Res. Comm. 2000, 276 (3), 1085-1088.
10. Hernández, M.; Pozo, L.; Gómez, I.; Melchor, A. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection. Biochem. Biophys. Res. Comm. 2000, 272 (1), 259-262.
11. Hernández, M.; Rodriguez, I.; Pozo, L.; Rivero, J. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1. Biochem. Biophys. Res. Comm. 2001 282 (1), 1-3.
12. Hernández, M.; Castellanos, P.; Márquez, Y.; Pozo, L.; Díaz, Y.; González, L.J. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus. Biochem. Biophys. Res. Comm. 2001, 289 (1), 1-6.
13. Hernández, M.; Castellanos, P.; Márquez, Y.; Pozo, L.; Díaz, Y.; González, L.J. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus Type II. Biochem. Biophys. Res. Comm. 2001, 289 (1), 7-12.
14. Merrifield, R.B. Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85, 2149-2154.
15. Sarin, V.K.; Kent, S.B.H.; Tam, J.P.; Merrifield, R.B. Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal. Biochem. 1981, 117, 147-157.
16. Tam, J.P.; Heath, W.F.; Merrifield, R.B. SN2 deprotection of synthetic peptides with a low concentration of HF in dimethyl sulfide: Evidence and application in peptide synthesis. J. Am. Chem. Soc. 1983, 105 (21), 6442-6455.
17. Burlingame, A.L.; Boyd, R.K.; Gaskell, S.J. Mass spectrometry. Anal. Chem. 1996, 68, 599R.
18. Biemann, K. Mass spectrometry of peptides and proteins. Ann. Rev. Biochem. 1992, 61, 977.
19. Bakhtiar, R.; Hofstadler, S.; Smith, R. Electrospray ionization mass spectrometry: Part II: Applications in characterization of peptides and proteins. J. Chem. Educ. 1996, 73, A118.
20. Chen, I.S.Y. Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame for the protease gene. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 3101-3105.